1. Home
  2. QDEL vs SNDX Comparison

QDEL vs SNDX Comparison

Compare QDEL & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$33.07

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.14

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
SNDX
Founded
1979
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
QDEL
SNDX
Price
$33.07
$20.14
Analyst Decision
Hold
Strong Buy
Analyst Count
6
12
Target Price
$39.33
$36.92
AVG Volume (30 Days)
821.9K
1.2M
Earning Date
02-11-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,714,400,000.00
$111,304,000.00
Revenue This Year
N/A
$620.14
Revenue Next Year
$2.42
$115.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
595.65
52 Week Low
$19.50
$8.58
52 Week High
$46.24
$22.73

Technical Indicators

Market Signals
Indicator
QDEL
SNDX
Relative Strength Index (RSI) 57.83 47.64
Support Level $31.87 $19.57
Resistance Level $35.58 $21.49
Average True Range (ATR) 1.67 1.04
MACD 0.07 -0.20
Stochastic Oscillator 61.04 21.16

Price Performance

Historical Comparison
QDEL
SNDX

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: